Your browser doesn't support javascript.
loading
Altered profile of plasma phospholipids in woman with recurrent pregnancy loss and recurrent implantation failure treated with lipid emulsion therapy.
Canella, Paula Renata Bueno Campos; Vinces, Salvador Sánchez; Silva, Álex Aparecido Rosini; Sanches, Pedro Henrique Godoy; Barini, Ricardo; Porcari, Andréia de Melo; Razolli, Daniela Soares; Carvalho, Patrícia de Oliveira.
Afiliación
  • Canella PRBC; Post Graduate Program in Health Sciences, São Francisco University, USF, Bragança Paulista, Brazil.
  • Vinces SS; Post Graduate Program in Health Sciences, São Francisco University, USF, Bragança Paulista, Brazil.
  • Silva ÁAR; Post Graduate Program in Health Sciences, São Francisco University, USF, Bragança Paulista, Brazil.
  • Sanches PHG; Post Graduate Program in Health Sciences, São Francisco University, USF, Bragança Paulista, Brazil.
  • Barini R; Department of Obstetrics and Gynecology, Campinas University (UNICAMP), São Paulo, Campinas, Brazil.
  • Porcari AM; Post Graduate Program in Health Sciences, São Francisco University, USF, Bragança Paulista, Brazil.
  • Razolli DS; Post Graduate Program in Health Sciences, São Francisco University, USF, Bragança Paulista, Brazil.
  • Carvalho PO; Post Graduate Program in Health Sciences, São Francisco University, USF, Bragança Paulista, Brazil.
Am J Reprod Immunol ; 89(3): e13673, 2023 03.
Article en En | MEDLINE | ID: mdl-36585861
BACKGROUND: Recurrent Pregnancy Loss (RPL) and Recurrent Implantation Failure (RIF) are highly heterogeneous condition and many of the mechanisms involved still require elucidation. The aim was to analyze the lipidomic profile in plasma of women with RPL and RIF before and after receiving the Lipid Emulsion Therapy (LET) containing 10% fish oil (SMOFlipid® 20%). METHODS: This study included twenty-six women with RPL or RIF from immunological or inflammatory causes, with elevated natural killer cell levels and divided into a Pregnancy Loss or a Live Birth group according to the outcome. The women received intravenous LET and sample collecting was done before the first, third and fifth dose of LET in the pregnant women. Ultra-performance liquid chromatography quadrupole time of flight mass spectrometry (UPLC-QTOF MS) and multivariate statistical methods were performed to evaluate the profile of phospholipids present in the women's plasma. RESULTS: An increase of phosphatidylcholines (PC) 40:8 and 36:5 levels with predominance of n6 polyunsaturated fatty acids (PUFA) was observed in plasma lipids of the Pregnancy Loss Group compared to Live Birth Group. We also observed an increase in the relative abundance of n3 PUFA-PC species (42:10 and 36:6) and LysoPC 15:0 with the long term use of LET. CONCLUSION: The greater availability of n3 PUFA in plasma of the pregnant women stemming from LET use can be considered advantageous regarding the alteration of the phospholipid profile and its postulated anti-inflammatory and immunomodulatory role.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácidos Grasos Omega-3 / Aborto Habitual Límite: Female / Humans / Pregnancy Idioma: En Revista: Am J Reprod Immunol Año: 2023 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Dinamarca

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ácidos Grasos Omega-3 / Aborto Habitual Límite: Female / Humans / Pregnancy Idioma: En Revista: Am J Reprod Immunol Año: 2023 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Dinamarca